FDA Grants Traditional Approval to Pirtobrutinib for Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma By Ogkologos - February 4, 2026 353 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the BRUIN-CLL-321 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Taking Time for the Everyday Things in 2024 December 29, 2023 NCI Expands Repository of Cancer Research Models: A Conversation with Drs.... April 20, 2018 Adding More Mushrooms to Your Diet May Decrease Your Risk of... April 21, 2021 ESMO Sarcoma & GIST Symposium 2022, 31 January – 2 February January 18, 2022 Load more HOT NEWS Efficacy and Safety of Patritumab Deruxtecan in Patients with EGFR-mutated NSCLC... How My Stage 4 Esophageal Cancer Diagnosis Led Me to a... El cáncer en mi comunidad: El rol de la detección del... Alzheimer’s-Linked Protein May Help Melanoma Spread to Brain
